Overview on Juvenile Idiopathic Arthritis: A Review
Ahlam Shary J. Hazazi *
University of Tabuk, Saudi Arabia.
Badaya Awadh M. Alshehri
University of Tabuk, Saudi Arabia.
Yara Abdulrahman Alali
University of Tabuk, Saudi Arabia.
Rahf Mohammed I. Alqarni
University of Tabuk, Saudi Arabia.
Ibtisam Shary J. Hazazi
University of Tabuk, Saudi Arabia.
Nujud Abdulqader Albalawi
University of Tabuk, Saudi Arabia.
Dimah Mohammed A. Abu Murad
University of Tabuk, Saudi Arabia.
Atheer Mansour E Alatawi
University of Tabuk, Saudi Arabia.
Nouf Ali Alatawi
University of Tabuk, Saudi Arabia.
Maisaa Mokhtar M. Yousuf
University of Tabuk, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
Juvenile idiopathic arthritis (JIA) is a broad term that refers to a clinically heterogeneous group of arthritis that develops before the age of 16 and has no recognized cause. JIA treatment has evolved during the last two decades. Clinical trials research has been directed at more specific therapeutics based on what has been discovered about the biology of disease. Pediatric rheumatologists now have many more medications to offer patients, with the expectation that their disease will be managed, thanks to advances in immune system research and the introduction of biologic drugs in the twenty-first century. Continuing development in these biological agents and discoveries new drugs as long as developing current gene analysis techniques is the best method to treat JIA and provide best quality of life.
Keywords: Juvenile idiopathic arthritis, oligoarthritis, polyarthritis, rheumatic disease